Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940493 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Newly Diagnosed Meningioma Patients
A Phase 2 study of Meningioma, sponsored by Nader Sanai.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05940493: Recruiting Phase 2 study of Meningioma, sponsored by Nader Sanai.
NCT05940493 is a Phase 2 study of Meningioma that is actively recruiting participants, run by Nader Sanai. The registered enrollment target is 72 participants, below the 96-participant average among 21 other Meningioma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05940493, a Phase 2 study of Meningioma, is actively recruiting participants, sponsored by Nader Sanai.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
Primary Outcome
Progression-free survival at 24 months (PFS24) will be analyzed using Kaplan-Meier methods.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abemaciclib
Study Locations (1)
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
What NCT05940493 shows while recruiting
NCT05940493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 96-participant average among 21 other Meningioma trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05940493 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05940493 about?
NCT05940493 is a clinical study titled "Abemaciclib in Newly Diagnosed Meningioma Patients". This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue c...
What is the current status of trial NCT05940493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2025-03-24. Estimated completion is 2030-09.
What conditions does trial NCT05940493 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT05940493?
The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05940493?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05940493 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05940493's enrollment target sits among peer trials
72 8th of 21 higher than 14 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI